Literature DB >> 31632766

Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation.

Chong-Kin Liam1, Mau-Ern Poh1, Yong-Sheng Liam2.   

Abstract

Entities:  

Year:  2019        PMID： 31632766      PMCID： PMC6783742          DOI： 10.21037/jtd.2019.08.117

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

1.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

2.  High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

Authors:  Ryo Ariyasu; Shingo Nishikawa; Ken Uchibori; Tomoko Oh-Hara; Takahiro Yoshizawa; Yosuke Dotsu; Junji Koyama; Masafumi Saiki; Tomoaki Sonoda; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Naohiko Inase; Kazuo Kasahara; Makoto Nishio; Ryohei Katayama
Journal:  Lung Cancer       Date:  2018-01-04       Impact factor: 5.705

3.  Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.

Authors:  Shang-Gin Wu; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; Jin-Yuan Shih
Journal:  ERJ Open Res       Date:  2017-07-12

4.  Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.

Authors:  Satoshi Igawa; Taihei Ono; Masashi Kasajima; Mikiko Ishihara; Yasuhiro Hiyoshi; Seiichiro Kusuhara; Noriko Nishinarita; Tomoya Fukui; Masaru Kubota; Jiichiro Sasaki; Mitsufuji Hisashi; Masanori Yokoba; Masato Katagiri; Katsuhiko Naoki
Journal:  Cancer Manag Res       Date:  2019-05-28       Impact factor: 3.989

5.  Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yasuhiro Kato; Yukio Hosomi; Kageaki Watanabe; Makiko Yomota; Shoko Kawai; Yusuke Okuma; Kaoru Kubota; Masahiro Seike; Akihiko Gemma; Tatsuru Okamura
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

6.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

7.  Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

Authors:  Jean Bernard Auliac; Maurice Pérol; David Planchard; Isabelle Monnet; Marie Wislez; Hélène Doubre; Florian Guisier; Eric Pichon; Laurent Greillier; Bénédicte Mastroianni; Chantal Decroisette; Roland Schott; Sylvestre Le Moulec; Jennifer Arrondeau; Alexis B Cortot; Laurence Gerinière; Aldo Renault; Catherine Daniel; Lionel Falchero; Christos Chouaid
Journal:  Lung Cancer       Date:  2018-11-27       Impact factor: 5.705

8.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Authors:  Glenwood Goss; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Jong Seok Lee; Gee-Chen Chang; Lucio Crino; Miyako Satouchi; Quincy Chu; Toyoaki Hida; Ji-Youn Han; Oscar Juan; Frank Dunphy; Makoto Nishio; Jin-Hyoung Kang; Margarita Majem; Helen Mann; Mireille Cantarini; Serban Ghiorghiu; Tetsuya Mitsudomi
Journal:  Lancet Oncol       Date:  2016-10-14       Impact factor: 41.316

9.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

10.  Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Authors:  Hiroaki Akamatsu; Nobuyuki Katakami; Isamu Okamoto; Terufumi Kato; Young Hak Kim; Fumio Imamura; Masaharu Shinkai; Rachel A Hodge; Hirohiko Uchida; Toyoaki Hida
Journal:  Cancer Sci       Date:  2018-05-31       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.